IDH1R132H Causes Resistance to HDAC Inhibitors by Increasing NANOG in Glioblastoma Cells

Biological Role and Therapeutic Potential of IDH Mutations in Cancer

(2018) Matthew S. Waitkus et al.   CANCER CELL

R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m 6 A/MYC/CEBPA Signaling

(2018) Rui Su et al.   CELL

IDH1/2Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors

(2018) Remco J. Molenaar et al.   CLINICAL CANCER RESEARCH

IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity

(2018) Mohammed Khurshed et al.   FASEB JOURNAL

Wild-type and mutated IDH1/2 enzymes and therapy responses

(2018) Remco J. Molenaar et al.   ONCOGENE

Depletion of HDAC1, 7 and 8 by Histone Deacetylase Inhibition Confers Elimination of Pancreatic Cancer Stem Cells in Combination with Gemcitabine

(2018) Mao-Hua Cai et al.   Scientific Reports

Emodin Sensitizes Hepatocellular Carcinoma Cells to the Anti-Cancer Effect of Sorafenib through Suppression of Cholesterol Metabolism

(2018) Young-Seon Kim et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Long noncoding RNA LINC00511 contributes to breast cancer tumourigenesis and stemness by inducing the miR-185-3p/E2F1/Nanog axis

(2018) Guanming Lu et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

IDH1: Linking Metabolism and Epigenetics

(2018) Silvia Raineri et al.   Frontiers in Genetics

Vanillin Suppresses Cell Motility by Inhibiting STAT3-Mediated HIF-1α mRNA Expression in Malignant Melanoma Cells

(2017) Eun-Ji Park et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Histone Deacetylase Inhibitors as Anticancer Drugs

(2017) Tomas Eckschlager et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

IDH1 mutation diminishes aggressive phenotype in glioma stem cells

(2017) Qi Yao et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence

(2017) Sevin Turcan et al.   NATURE GENETICS

2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity

(2017) Parker L. Sulkowski et al.   Science Translational Medicine

IDH1 Mutation Promotes Tumorigenesis by Inhibiting JNK Activation and Apoptosis Induced by Serum Starvation

(2017) Bin Jiang et al.   Cell Reports

Expression of CD133 and CD44 in glioblastoma stem cells correlates with cell proliferation, phenotype stability and intra-tumor heterogeneity

(2017) Daniel V. Brown et al.   PLoS One

A Brain Penetrant Mutant IDH1 Inhibitor Provides In Vivo Survival Benefit

(2017) Johnny Kopinja et al.   Scientific Reports

Expression of Idh1R132H in the Murine Subventricular Zone Stem Cell Niche Recapitulates Features of Early Gliomagenesis

(2016) Chiara Bardella et al.   CANCER CELL

R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling

(2016) Daming Cui et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Targeting SOX2 as a Therapeutic Strategy in Glioblastoma

(2016) Laura Garros-Regulez et al.   Frontiers in Oncology

The oncometabolite R-2-hydroxyglutarate activates NF-κB-dependent tumor-promoting stromal niche for acute myeloid leukemia cells

(2016) Jing-Yi Chen et al.   Scientific Reports

Oncometabolite D-2-Hydroxyglurate Directly Induces Epithelial-Mesenchymal Transition and is Associated with Distant Metastasis in Colorectal Cancer

(2016) Hugh Colvin et al.   Scientific Reports

Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198

(2015) R. J. Molenaar et al.   CANCER RESEARCH

2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling

(2015) Xudong Fu et al.   Cell Metabolism

IDH1R132H decreases the proliferation of U87 glioma cells through upregulation of microRNA-128a

(2015) QUAN-MIN NIE et al.   Molecular Medicine Reports

IDH1R132H mutation causes a less aggressive phenotype and radiosensitizes human malignant glioma cells independent of the oxygenation status

(2015) Jacqueline Kessler et al.   RADIOTHERAPY AND ONCOLOGY

Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype

(2015) Elisabet Cuyàs et al.   Oncotarget

IDH1 Overexpression Induced Chemotherapy Resistance and IDH1 Mutation Enhanced Chemotherapy Sensitivity in Glioma Cells in Vitro and in Vivo

(2014) Ju-Bo Wang et al.   Asian Pacific Journal of Cancer Prevention

Knockdown of NANOG enhances chemosensitivity of liver cancer cells to doxorubicin by reducing MDR1 expression

(2014) JIA-JIA ZHOU et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

New and emerging HDAC inhibitors for cancer treatment

(2014) Alison C. West et al.   JOURNAL OF CLINICAL INVESTIGATION

Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience

(2014) Pavel Bezecny   MEDICAL ONCOLOGY

Intracellular α-ketoglutarate maintains the pluripotency of embryonic stem cells

(2014) Bryce W. Carey et al.   NATURE

Emerging role of nanog in tumorigenesis and cancer stem cells

(2013) Luis E. IV Santaliz-Ruiz et al.   INTERNATIONAL JOURNAL OF CANCER

IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma

(2013) Chunzhi Zhang et al.   NEURO-ONCOLOGY

An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells

(2013) D. Rohle et al.   SCIENCE

IDH mutation impairs histone demethylation and results in a block to cell differentiation

(2012) Chao Lu et al.   NATURE

Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation

(2012) Peppi Koivunen et al.   NATURE

IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics

(2012) Masato Sasaki et al.   NATURE

Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation

(2012) Sichen Li et al.   NEURO-ONCOLOGY

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

(2011) Wei Xu et al.   CANCER CELL

Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures

(2011) Bin-Kuan Chou et al.   CELL RESEARCH

The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate

(2010) Patrick S. Ward et al.   CANCER CELL

NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53

(2010) Marie Zbinden et al.   EMBO JOURNAL

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

(2010) Stefan Gross et al.   JOURNAL OF EXPERIMENTAL MEDICINE

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas

(2010) C. Houillier et al.   NEUROLOGY

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2009) Lenny Dang et al.   NATURE

Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome

(2009) Elaine R. Mardis et al.   NEW ENGLAND JOURNAL OF MEDICINE

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors

(2008) Ittai Ben-Porath et al.   NATURE GENETICS

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE